CHMP Backs Benralizumab for Severe Eosinophilic Asthma CHMP Backs Benralizumab for Severe Eosinophilic Asthma

Benralizumab targets the interleukin-5 receptor on the surface of eosinophils and basophils to reduce eosinophilic inflammation.International Approvals

Source: Medscape Medical News Headlines - November 10, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news